Biogen | BIIB - Current Liabilities



Biogen reported $3.18B in Current Liabilities for its fiscal quarter ending in June of 2025.


Current Liabilities Change Date
AbbVie USD 36.4B 2.35B Mar/2025
Acadia Pharmaceuticals USD 330.02M 27.49M Jun/2025
ALKERMES USD 505.96M 62.23M Jun/2025
Amgen USD 20.48B 2.53B Jun/2025
Bayer EUR 29.78B 1.82B Jun/2025
Biogen USD 3.18B 2.11B Jun/2025
BioMarin Pharmaceutical USD 684.25M 56.03M Jun/2025
Bristol-Myers Squibb USD 27.53B 3.46B Jun/2025
Eli Lilly USD 39.02B 8.95B Jun/2025
Gilead Sciences USD 11.19B 1.15B Jun/2025
Incyte USD 1.28B 608.18M Jun/2025
Merck USD 26.04B 863M Jun/2025
Moderna USD 1.57B 32M Jun/2025
Neurocrine Biosciences USD 546.3M 23.4M Jun/2025
Novartis USD 31.71B 95M Jun/2025
Pfizer USD 37.73B 1.27B Jun/2025
PTC Therapeutics USD 627.81M 32.42M Jun/2025
Regeneron Pharmaceuticals USD 3.67B 100.4M Jun/2025
Sanofi 29.06B 3.16B Jun/2025
Sanofi 29.06B 103M Jun/2025
Sarepta Therapeutics USD 919.95M 314.36M Jun/2025
Teva Pharmaceutical Industries USD 11.86B 704M Jun/2025
Ultragenyx Pharmaceutical USD 293.24M 1.58M Jun/2025
United Therapeutics USD 527.1M 194.4M Jun/2025
Vertex Pharmaceuticals USD 4.14B 355.2M Jun/2025